solventdeterg
sd
process
use
plasma
safe
inactiv
lipidenvelop
virus
introduct
specif
prionbind
ligand
gel
combin
sd
treatment
timereduc
h
still
ensur
effici
viru
kill
reduc
abnorm
prion
protein
log
step
preserv
level
plasmin
inhibitor
close
refer
rang
infect
known
nonenvelop
virus
hav
parvoviru
prevent
ensur
low
viru
load
start
plasma
unit
dilut
pool
singl
plasma
unit
neutral
immun
antibodi
alreadi
present
initi
plasma
pool
major
advantag
sd
plasma
fresh
frozen
plasma
pathogeninactiv
plasma
extrem
safeti
respect
transfusionrel
acut
lung
injuri
significantli
lower
likelihood
provok
allerg
reaction
advantag
best
interpret
result
dilut
effect
pool
fewer
clinic
studi
cover
indic
plasma
extens
clinic
experi
shown
reduc
level
coagul
factor
inhibitor
result
sd
treatment
impair
significantli
clinic
efficaci
toler
plasma
properli
standard
clot
factor
inhibitor
potenc
low
batchtobatch
variat
compar
singledonor
plasma
unit
make
sd
plasma
suitabl
standard
treatment
solventdetergensbehandelt
plasma
pathogeninaktivierung
transfusionsassoziiert
akut
lungeninsuffizienz
allergisch
reaktionen
klinisch
wirksamkeit
da
plasma
angewandt
solventdetergen
sd
verfahren
inaktiviert
all
viren
sicher
die
mit
dem
einsatz
ein
spezifischen
prionen
bindenden
ligandengel
redukt
der
inkubationszeit
mit
sd
von
auf
h
stellt
weiterhin
ein
inaktivierung
aller
viren
sicher
reduziert
abnorm
prionenprotein
um
logstufen
und
resultiert
die
nur
unterhalb
de
referenzbereich
liegen
infektionen
mit
viren
wie
hav
und
parvoviru
werden
durch
sicherstellung
niedrig
virusbelastungen
im
ausgangsmateri
durch
da
poolen
von
einzelspenderplasmen
und
durch
im
plasmapool
enthalten
neutralisierend
verhindert
die
wesentlichen
vorteil
von
sdplasma
gefrorenem
frischplasma
gfp
und
anderen
pathogeninaktivierten
einzelspenderplasmen
bestehen
seiner
hohen
sicherheit
bezug
auf
da
risiko
die
transfusionsassoziiert
akut
lungeninsuffizienz
und
deutlich
wenig
allergischen
reaktionen
beid
vorteil
auf
die
durch
da
poolen
sein
mindesten
klinisch
studien
die
all
indikationen
plasma
umfassten
und
umfassend
klinisch
erfahrung
haben
gezeigt
dass
die
im
sdplasma
gfp
etwa
reduzierten
konzentrationen
der
gerinnungsfaktoren
und
inhibitoren
zu
keiner
signifikanten
minderung
der
klinischen
wirksamkeit
und
die
im
sdplasma
gut
standardisierten
der
gerinnungsfaktoren
und
inhibitoren
und
niedrig
schwankungen
von
charg
zu
charg
erlauben
ein
besser
standardisiert
therapi
mit
sdplasma
al
mit
hellsternsolheim
sd
plasma
mixtur
remov
solvent
deterg
sd
treatment
preced
filtrat
filter
remov
cell
debri
follow
steril
filtrat
bag
vial
use
filter
asept
fill
manufactur
sd
plasma
red
cross
center
hagen
underway
octapharma
introduc
process
factori
vienna
licens
process
french
transfus
servic
began
manufactur
sd
plasma
centr
de
transfus
sanguin
crt
bordeaux
latter
half
nation
bioproduct
institut
nbi
pinetown
south
africa
develop
aboindepend
univers
plasma
bioplasma
fdp
use
sd
treatment
manufactur
process
licens
octapharma
univers
sd
plasma
develop
octapharma
work
titl
unipla
final
stage
licens
kedrion
castelvecchio
pascoli
itali
introduc
sd
plasma
plasmasaf
also
use
octapharma
licens
manufactur
process
product
sd
plasma
german
red
cross
center
hagen
end
usa
feder
drug
administr
fda
attitud
toward
sd
plasma
becam
gradual
posit
manufactur
sd
plasma
use
mani
procedur
pioneer
europ
octapharma
began
initi
melvil
biolog
divis
nybc
later
due
lack
adequ
resourc
nybc
manufactur
transfer
spinoff
vi
technolog
inc
vitex
vitex
watertown
usa
subsequ
produc
american
sd
plasma
plassd
tm
except
differ
plasma
pool
size
l
franc
l
germani
south
africa
l
austria
l
usa
sd
plasma
recent
manufactur
similar
though
ident
method
today
octapharma
launch
octaplaslg
sd
plasma
whose
manufactur
involv
addit
chromatograph
step
combin
specif
prionbind
ligand
gel
sd
treatment
timereduc
h
minipool
l
plasma
sd
treatment
may
perform
close
multibag
system
tnbp
tnbp
triton
use
instead
triton
sd
treatment
perform
h
follow
oil
extract
step
option
follow
hydrophob
chromatographi
pathogen
reduct
solvent
tnbp
incub
temperatur
increas
minipool
system
pioneer
burnouf
collabor
egyptian
blood
banker
use
gmp
condit
blood
bank
resourcelimit
countri
featur
differ
sd
plasma
product
shown
tabl
sd
treatment
plasma
result
prompt
larg
reduct
envelop
virus
high
reserv
capac
inactiv
rate
envelop
virus
plasma
solventdeterg
sd
method
inactiv
envelop
virus
plasma
protein
prepar
first
develop
earli
method
prove
effect
process
coagul
factor
concentr
disrupt
membran
lipidenvelop
virus
cell
protozoa
leav
labil
coagul
factor
intact
efficaci
respect
bacteria
variabl
gener
ineffect
nonlipidenvelop
virus
sd
process
wide
use
best
valid
robust
pathogen
inactiv
technolog
known
today
mani
million
dose
sdtreat
plasma
protein
transfus
without
report
transmiss
envelop
virus
unlik
coagul
factor
concentr
composit
plasma
complex
effect
plasma
transfus
medicin
depend
heavili
protein
seem
resist
sd
treatment
bernhard
horowitz
propos
develop
method
treat
plasma
sd
unabl
arous
interest
find
financ
usa
turn
octapharma
octapharma
ag
lachen
switzerland
agre
financ
laboratori
effort
new
york
blood
center
nybc
exchang
european
market
right
laboratori
work
complet
year
initi
experiment
process
hand
octapharma
work
german
red
cross
center
hagen
germani
octapharma
matur
laboratori
process
form
suitabl
industrialscal
manufactur
character
manufactur
product
publish
time
also
horowitz
collabor
publish
result
biesert
shartono
subsequ
valid
robust
sd
plasma
treatment
studi
viru
safeti
octapla
octapharma
ag
lachen
switzerland
concentr
tri
nbutyl
phosphat
tnbp
increas
accommod
lipid
content
plasma
temperatur
rais
h
ensur
effici
viru
kill
sodium
cholat
usual
deterg
use
sd
treatment
coagul
factor
substitut
polyoxyethyleneptoctylphenol
triton
easili
remov
togeth
tnbp
simpl
effect
hydrophob
chromatograph
step
tnbp
act
organ
solvent
remov
lipid
membran
pathogen
use
alon
protocol
triton
nonion
deterg
stabil
tnbp
disrupt
lipid
bilay
thu
eas
extract
lipid
process
final
step
involv
ad
soybean
castor
oil
sd
treatment
effect
nonenvelop
virus
immun
antibodi
commonli
present
plasma
provid
measur
protect
infect
commonli
encount
nonenvelop
virus
hav
parvoviru
upper
limit
hav
parvoviru
viru
particl
plasma
pool
minimum
titer
correspond
neutral
antibodi
present
plasma
pool
provid
addit
safeti
octapharma
license
minim
risk
emerg
transfusiontransmit
infect
use
pool
size
l
much
smaller
l
use
plasma
protein
fraction
concomit
pathogen
reduct
regard
prion
combin
prion
ligand
gel
reduct
prion
alreadi
obtain
sd
treatment
process
result
log
reduct
abnorm
prion
protein
prpsc
octaplaslg
extrem
high
viru
load
drop
detect
level
log
step
less
min
except
vaccinia
viru
inactiv
take
min
far
test
envelop
virus
includ
recent
emerg
virus
west
nile
viru
chikungunya
viru
new
influenza
strain
sever
acut
respiratori
syndrom
coronaviru
vulner
sd
process
octapharma
factori
austria
togeth
license
germani
red
cross
center
hagen
franc
crt
bordeaux
itali
kedrion
south
africa
nbi
pinetown
deliv
approxim
million
unit
sd
plasma
use
routin
medic
care
efficaci
sd
treatment
process
underscor
fact
document
case
infect
hbv
hcv
hiv
result
transfus
sd
plasma
report
follow
origin
incub
time
provid
excess
margin
safeti
permit
reduct
incub
time
h
octaplaslg
safeti
margin
still
superior
pathogenreduc
technolog
octapla
license
produc
optim
separ
frozen
plasma
reduct
clot
factor
inhibitor
activ
final
composit
similar
ffp
factor
viii
activ
lower
ffp
protein
activ
reduc
plasmin
inhibitor
activ
level
l
pool
normal
french
sd
plasma
produc
l
pool
plasmin
inhibitor
level
normal
minipool
sd
plasma
protein
plasmin
inhibitor
reduc
normal
plassd
pool
size
l
less
strict
qualiti
requir
separ
freez
plasma
strikingli
lower
activ
protein
plasmin
inhibitor
plasmin
activ
inhibitor
antitrypsin
octapla
new
octaplaslg
sd
treatment
reduc
h
activ
plasmin
inhibitor
increas
normal
thu
incub
time
stress
due
pool
size
plasma
qualiti
appear
affect
plasmin
inhibitor
burnouf
et
al
also
specul
triton
might
affect
plasmin
inhibitor
avoid
use
smaller
compound
triton
bleed
problem
liver
transplant
octapla
produc
ireland
american
plasma
may
due
neg
effect
caus
delay
freez
begin
day
collect
earli
sd
plasma
consid
blood
product
germani
franc
european
countri
treat
medicin
product
use
sd
plasma
often
permit
registr
process
obviou
viru
safeti
particularli
regard
hcv
sd
plasma
first
introduc
german
feder
state
north
rhinewestphalia
norway
sd
plasma
replac
ffp
follow
success
clinic
trial
current
ordinari
medicin
licens
requir
sd
plasma
european
countri
except
franc
class
label
blood
product
octapla
licens
biopharmaceut
product
countri
worldwid
far
octaplaslg
approv
use
germani
australia
regulatori
procedur
ongo
european
countri
confirmatori
studi
claim
capac
remov
prion
request
countri
near
complet
approv
process
unipla
also
final
stage
te
svae
octapharma
person
commun
usa
regulatori
approv
long
delay
compar
europ
fda
attitud
toward
sd
plasma
began
chang
clinic
data
accumul
becam
clear
us
approv
sd
plasma
justifi
requir
suffici
product
capac
unitsyear
nationlevel
distribut
partner
delay
fda
approv
vitex
increas
product
capac
sd
plasma
suffici
american
red
cross
arc
select
sole
distributor
heat
debat
ensu
rang
question
medic
scientif
concern
rise
health
care
cost
poten
european
pharmacopoeia
juli
prescrib
residu
amount
sd
plasma
greater
tnbp
triton
valu
far
toxic
level
either
substanc
ambient
environment
exposur
industri
societi
actual
level
sd
plasma
batch
detect
level
respect
leukocyt
antibodi
detect
pool
l
smaller
french
l
pool
regularli
screen
one
pool
found
posit
discard
find
best
explain
dilut
effect
possibl
neutral
leukocyt
antibodi
leukocyt
cell
fragment
present
origin
plasma
pool
remov
sd
treatment
dilut
may
also
play
role
significantli
reduc
frequenc
sever
allerg
reaction
observ
follow
transfus
sd
plasma
compar
methylen
blue
plasma
psoralen
plasma
quarantin
plasma
substanti
safeti
sd
treatment
wit
transfus
million
unit
sd
plasma
report
toxic
transfusionassoci
lung
injuri
trali
antibodi
neoantigen
observ
neoantigen
report
establish
pathogen
reduct
procedur
involv
treatment
methylen
blue
psoralen
riboflavin
sd
result
loss
factor
viii
activ
less
coagul
factor
inhibitor
due
dilut
thaw
freez
consid
wide
refer
rang
clot
factor
inhibitor
singl
plasma
unit
reduct
order
magnitud
seem
clinic
signific
qualiti
fresh
frozen
plasma
ffp
use
pathogen
reduct
may
also
vari
wide
exampl
optim
freez
storag
temperatur
import
sourc
plasma
way
separ
time
interv
collect
separ
freez
crucial
apheresi
plasma
frozen
promptli
collect
best
follow
recov
plasma
frozen
within
h
superior
frozen
within
h
delay
prolong
freez
reduc
coagul
factor
proteas
activ
repeat
thaw
refreez
particularli
affect
coagul
factor
v
viii
xi
final
blood
group
individu
significantli
lower
factor
viii
von
willebrand
factor
vwf
plasma
level
subject
abo
blood
group
sd
treatment
target
lipid
littl
effect
transfusionrelev
protein
plasma
pool
uniform
product
unit
volum
ml
sd
plasma
low
batchtobatch
variat
plasma
level
coagul
factor
inhibitor
antibodi
allow
clinician
predict
plasma
transfus
effect
precis
sd
plasma
octapharma
octapla
sinc
demonstr
patient
group
includ
preterm
infant
liver
transplant
patient
transfus
sd
plasma
special
product
reconstitut
blood
prepar
use
sd
plasma
similar
experi
except
bleed
problem
liver
transplant
report
ireland
approxim
unit
octapla
transfus
bleed
problem
could
ascrib
recov
american
plasma
use
product
octapla
batch
ireland
far
liver
transplant
perform
good
result
oslo
univers
hospit
rikshospitalet
oslo
sd
plasma
plasma
compon
case
thromboembol
ascrib
use
due
low
content
plasmin
inhibitor
octapla
aprotinin
initi
use
frequent
sever
liver
failur
thu
complic
repeat
cardiac
surgeri
aprotinin
success
substitut
tranexam
acid
cardiac
surgeri
liver
transplant
except
liver
transplant
patient
requir
broad
spectrum
serin
proteas
inhibitor
portug
also
good
experi
octapla
sinc
introduct
howev
knowledg
without
scientif
document
far
hemovigil
data
franc
norway
finland
show
signific
reduct
approxim
seriou
advers
event
respect
trali
document
event
ever
report
sd
plasma
uk
unit
octapla
transfus
introduct
seriou
hazard
transfus
hemovigil
system
without
report
seriou
problem
switch
sd
plasma
annual
rate
clinic
use
shown
littl
chang
ireland
finland
norway
experienc
increas
l
per
million
inhabit
sinc
still
mean
consumpt
l
per
million
inhabit
western
europ
l
per
million
germani
cl
van
der
poel
sanquin
netherland
person
commun
fact
sd
plasma
clear
standard
solut
defin
constant
volum
advers
event
made
particularli
popular
among
anesthesiologist
surgeon
comparison
properti
differ
type
therapeut
plasma
present
tabl
tial
impact
blood
center
blood
bank
revenu
product
control
introduct
plassd
arc
logo
fact
arc
exclus
us
distributor
provok
strong
reaction
member
america
blood
center
collect
distribut
half
nation
blood
suppli
addit
arc
set
price
plassd
higher
expect
along
number
thromboembol
advers
reaction
observ
european
sd
plasma
result
termin
sd
plasma
product
usa
gener
even
high
plasma
dose
result
moder
increas
coagul
factor
inhibitor
plasma
level
recipi
sever
indic
plasma
base
strong
evid
result
control
clinic
trial
fewer
recent
review
studi
retrospect
analys
cover
indic
plasma
conduct
examin
efficaci
toler
sd
plasma
two
examin
use
univers
sd
plasma
unipla
openheart
surgeri
adult
undergo
elect
liver
resect
though
studi
lack
statist
power
detect
minor
differ
due
small
size
clearli
show
loss
coagul
factor
inhibitor
level
caus
sd
treatment
result
signific
loss
clinic
efficaci
toler
concern
low
level
plasmin
inhibitor
protein
antitrypsin
activ
sd
plasma
confirm
clinic
studi
claim
thrombosi
hyperfibrinolyt
bleed
trigger
reduc
protein
low
plasmin
inhibitor
potenc
octapla
withstood
critic
review
notwithstand
higher
level
plasmin
inhibitor
octaplaslg
approach
lower
normal
refer
rang
welcom
clinic
experi
sd
plasma
also
substanti
product
safeti
experi
franc
transfus
million
unit
plasma
solvant
deterg
sinc
norway
unit
octapla
sinc
finland
unit
hellsternsolheim
due
dilut
effect
antibodi
allergen
discount
possibl
sd
treatment
direct
indirect
effect
activ
lipid
associ
trali
author
declar
conflict
interest
major
advantag
sd
plasma
ffp
pathogen
inactiv
plasma
extrem
safeti
regard
trali
anoth
advantag
sd
plasma
ffp
markedli
lower
rate
allerg
reaction
advantag
sd
plasma
respect
trali
best
explain
dilut
effect
pool
possibl
neutral
antibodi
residu
leukocyt
solubl
antigen
plasma
unit
lower
number
allerg
reaction
like
